NASH is a severe form of non-alcoholic fatty liver disease without any FDA-approved treatments. However, many companies are working towards an effective treatment, with several in late-stage trials. Five leading contenders are Galectin Therapeutics with its product belapectin; Galmed Pharmaceuticals with Aramchol; Inventiva Pharma with lanifibranor; Madrigal Pharmaceuticals with resmetirom; and 89bio with pegozafermin. The NASH treatment market is expected to reach $48.3 billion by 2035.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
